HU is a typical RNR inhibitor that targets RRM2 and has long been used for cancer therapy in the clinic, including chronic myelogenous leukaemia, AML, and other haematological malignancies. Here, RRM2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.